Navigation Links
Warner Chilcott Agrees to Terminate Existing Co-Promotion Agreement and Acquire U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
Date:9/24/2010

rol of sales and marketing of Enablex for the U.S. market, and expects to assume manufacturing control for the U.S. within three years.

Prior to this announcement, Warner Chilcott co-promoted Enablex with Novartis in the U.S. pursuant to an agreement that it assumed upon its purchase of the global branded prescription pharmaceuticals business of The Procter & Gamble Company in October 2009.  Under the terms of the co-promotion agreement, Warner Chilcott and Novartis shared development and promotion costs relating to the U.S. Enablex business and Warner Chilcott received a contractual percentage of Novartis' sales of Enablex in the U.S., which Warner Chilcott recorded on a net basis in "other revenue".  Under that agreement, Warner Chilcott was also obligated to incur an agreed upon amount for advertising, promotion and selling costs each fiscal year.  Following completion of the transaction, Warner Chilcott will recognize all sales of Enablex in the U.S. as revenues, as well as all expenses relating to such sales.  The Company expects this transaction will have a modestly accretive impact on the Company's 2010 adjusted cash net income and adjusted cash net income per share following the closing.

Enablex was approved by the U.S. Food and Drug Administration in 2004 for the treatment of overactive bladder, and launched in 2005.

About Warner Chilcott Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is fully integrated with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-F.

Forward Looking Statements This press release contains forward-looking statements concerning our operations, our anticipated financial performance and financial condition, and our business plans
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Warner Chilcott Announces $500 Million Senior Notes Offering in Connection With Agreement to Acquire U.S. Rights to Enablex®
2. Warner Chilcott to Present at UBS Global Life Sciences Conference
3. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
4. Warner Chilcott Completes Amendment to Existing Senior Secured Credit Facilities and Closes Senior Notes Offering; Company Declares Special Cash Dividend of $8.50 Per Share and Updates Full-Year 2010 Financial Guidance
5. Warner Chilcott Announces Earnings Release Date and Conference Call for Second Quarter 2010 Financial Results
6. Warner Chilcott Announces 3-Month Extension of PDUFA Date on Next Generation Actonel Product
7. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
8. Warner Chilcott to Present at the Wells Fargo Securities Healthcare Conference
9. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott Announces 2010 Financial Guidance Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... ... September 01, 2015 , ... ... to announce its new fall collection. Every customer who buys an Earth Brand ... the company’s environmental partnership with Trees for the Future, a nonprofit dedicated to ...
(Date:9/1/2015)... ... ... Celebrity hairstylist and Beauty Gives Back Art Team member Ted Gibson in ... Oct. 1, at the La Valencia Hotel. The presentation, on the eve of Fashion ... professional hair, makeup and nail design. , The evening of beauty and fashion ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... options to efficiently cure and prevent different malignancies. Some options for cancer ... pathophysiological properties due to which distinctive approach is necessary for effective treatment. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Virginia ... Machine,” is still strongly maintaining her firm’s success in the hair care and ... her upcoming city-to-city tour, Ellis will be providing “Look and learn” live demonstrations, ...
(Date:9/1/2015)... ... 01, 2015 , ... PetPace, the provider of an innovative ... activity, today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Practice Management Software packages in the US. Practice Management Software helps veterinarians manage ...
Breaking Medicine News(10 mins):Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 2Health News:Earth Brands Footwear Partners with Trees for the Future for Launch of Fall Collection: Buy Shoes, Plant a Tree 3Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 2Health News:Celebrity Hairstylist Ted Gibson Explores Fusion of Fashion and Beauty at “Beauty Behind the Fashion” at Fashion Week San Diego Proceeds to benefit THIRST Project 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2
... powers introduced by the government to enable specially trained ... been successfully adopted, according to a new report. ... Keele found widespread acceptance of the new powers among ... for the type of medical conditions being treated. ...
... HealthDay Reporter , MONDAY, May 9 (HealthDay News) -- ... nervous system disease known as amyotrophic lateral sclerosis (ALS), British ... does not mean people with long ring fingers will develop ... risk for it. "We have not done a study ...
... By Alan Mozes HealthDay Reporter , MONDAY, ... link specific behaviors and health conditions to the onset of ... anything you do or don,t do will prevent the brain ... The U.S. National Institutes of Health convened a ...
... at Scripps Institution of Oceanography at UC San Diego ... known to produce substances potentially useful against human diseases. ... the oldest forms of life on the planet. At ... to humans and animals. But despite the recognized capability ...
... MONDAY, May 9 (HealthDay News) -- Could gastric bypass weight-loss ... That,s the finding from a group of Swedish researchers who ... the Digestive Disease Week conference in Chicago. A team ... patients who underwent primary bariatric surgery between 1980 and 2006. ...
... MONDAY, May 9 (HealthDay News) -- Overdiagnosis and overtreatment of ... to the large increase in the use of computed tomography ... embolism (PE) is a potentially life-threatening blood clot in the ... PE and its use has grown rapidly, according to background ...
Cached Medicine News:Health News:Wide-reaching report finds strong support for nurse and pharmacist prescribing 2Health News:Ring Finger Length Linked to ALS, Study Suggests 2Health News:Ring Finger Length Linked to ALS, Study Suggests 3Health News:Little Evidence That Diet, Lifestyle Cuts Alzheimer's Risk 2Health News:Little Evidence That Diet, Lifestyle Cuts Alzheimer's Risk 3Health News:Genome of marine organism reveals hidden secrets 2Health News:Genome of marine organism reveals hidden secrets 3Health News:Risk for Problem Drinking May Rise After Gastric Bypass 2Health News:Scan Technology Tied to Overtreatment of Clots in Lungs 2
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: